Quick Update: Advanced Micro Devices, Inc. (NYSE:AMD); Twitter Inc. (NYSE:TWTR) And DARA Biosciences Inc (NASDAQ:DARA)

Boston, MA, 02/26/2014  (usastockreport) – Advanced Micro Devices, Inc. (NYSE:AMD) announced the availability of the latest BlueStacks dual OS Android solution to the retail segment at the Mobile World Congress on Tuesday. The extension of the virtualized solution to the retail stores will enable consumers to easily use both Windows and Android simultaneously, on exclusive AMD-based PCs. The BlueStacks solution will be offered in EMEA, with key retail partners, later this year. The consumers buying PC will have the option of an Advanced Micro Devices, Inc. (NYSE:AMD)-BlueStacks version upgrade at select retailers. The convenient combination of Blue Stacks will help to bridge the gap between mobile and PC for retail customers.

If reports from research firm Nielsen are to be believed that the micro-blogging site Twitter Inc. (NYSE:TWTR) is gaining some strength in terms of user growth on mobile. The company had been under the spotlight for reporting sluggish growth in users in the fourth quarter, but now reports are indicating that it is swinging back to a healthy growth in its mobile app. As per the study, nearly 80% of Twitter Inc. (NYSE:TWTR)’s users in UK access the micro-blogging site through their mobile devices.

DARA Biosciences Inc (NASDAQ:DARA) zoomed by over 23% yesterday after the drugmaker received Orphan Drug status from the FDA for its KRN5500. The company’s drug KRN5500 is aimed at treating severe and chronic neuropathic pain triggered by chemotherapy. After the FDA’s grant, DARA is expected to look out for more financing options in order to engage in further development of this drug. At the beginning of the month, Zacks research analyst Jason Napodano mentioned in his report that if KRN5500 gets ‘orphan drug designation’ from the FDA then it could boost the market value of DARA Biosciences Inc (NASDAQ:DARA) by up to three times. Additionally, Napodano also anticipated that the company might pull in a licensing partner post receiving Orphan Drug status.

Like it? Share it!

Leave A Response